- Report
- July 2024
- 288 Pages
Global
From €5389EUR$5,885USD£4,350GBP
- Report
- March 2025
- 175 Pages
Global
From €4256EUR$4,490USD£3,555GBP
- Report
- May 2023
- 169 Pages
Global
From €2227EUR$2,350USD£1,861GBP
- Report
- May 2021
- 50 Pages
China
From €2464EUR$2,600USD£2,059GBP
- Report
- January 2024
- 200 Pages
Global
From €3933EUR$4,150USD£3,286GBP
- Report
- June 2019
- 18 Pages
Global
€9478EUR$10,000USD£7,918GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €474EUR$500USD£396GBP
- Report
- June 2019
- 15 Pages
Japan
€9478EUR$10,000USD£7,918GBP
- Report
- November 2023
- 35 Pages
Global
From €3497EUR$3,690USD£2,922GBP
Tivicay (dolutegravir) is a medication used to treat HIV/AIDS. It is a type of antiretroviral drug, which works by blocking the action of an enzyme called reverse transcriptase, which is needed for the virus to replicate. Tivicay is used in combination with other antiretroviral drugs to treat HIV infection. It is approved for use in adults and children over the age of 12.
The Tivicay market is a rapidly growing segment of the HIV/AIDS drug market. It is a highly competitive market, with several major players offering their own versions of the drug. The market is also characterized by a high degree of innovation, with new formulations and delivery systems being developed to improve the efficacy and safety of the drug.
The major players in the Tivicay market include Gilead Sciences, ViiV Healthcare, Merck, and Bristol-Myers Squibb. Other companies in the market include GlaxoSmithKline, Janssen Pharmaceuticals, and Teva Pharmaceuticals. Show Less Read more
